Jin-Soo Kim

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

Jake June-Koo Lee, Junehawk Lee, Sehui Kim et al. · Journal of Clinical Oncology · 2017 · 498 citations

Pathology, Purpose Histologic Transformation, Genetic Predictors +20

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 133 citations · Full text

Raf Inhibitor Belvarafenib, Melanoma, Pathology +6

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee et al. · The Lancet Oncology · 2019 · 132 citations

Dose Expansion Parts, Dose Escalation, Medicine +8

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Byoung Chul Cho, Ji‐Youn Han, Sang‐We Kim et al. · Journal of Thoracic Oncology · 2021 · 88 citations · Full text